FTSE 100 fagged out as US Food and Drug Administration targets nicotine levels in cigarettes
Despite the beating meted out to IMPs and BATs, the Footsie rallied in the last half hour to trim its heavy losses
Company
AstraZeneca PLC
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1076 stories · page 9 of 11
Diageo - Up 7% and trading ahead of expectations, but still being whupped by its rivals
Liberum’s price target is £20 a share, which is £4.32 below the current price
AstraZeneca – long road back for toxic drug giant
There was a lot of hope and expectation factored into the share price ahead of the findings with AZ up 20% from January
Billions wiped off AstraZeneca’s value as key lung cancer study fails to meet primary endpoint
It had been hoped that the combination of two of its lead immuno-oncology compounds, Imfinzi and tremelimumab, would lead the drugmaker into a new era
Archive
FTSE 100 closes nine points lower as AstraZeneca weighs
It's been a busy day here in London; 15% of FTSE 100-listed companies have had some sort of meaningful news out...
Archive
Lloyds to report strong quarterly figures in first results since government sold remaining stake
Lloyds Banking Group and Royal Dutch Shell are among a slew of companies reporting earnings on Thursday
Archive
Lloyds and Barclays to dominate manic week of corporate earnings
Week ahead: Lloyds, Barclays, AstraZeneca, GlaxoSmithKline, Sky, Reckitt Benckiser
FTSE 100 ends lower but European shares fare worse
London stocks were on the front foot this morning, but they quickly retreated this afternoon...
Archive
Rookie Investor: If you’re under 40, why haven’t you opened a Lifetime ISA?
Of course if you’ve already done so, this article probably doesn’t apply to you…
FTSE 100 fades despite demand for miners
The Footsie closed down on the day but up on the week
AstraZeneca plummets on reports that CEO Pascal Soriot is set to join Israeli competitor Teva
Financial news website Calcalist has reported that Soriot is close to being unveiled as Teva’s new boss
Investments and investor services
FTSE 100 closes down a shade with BT Group plc top dog
Footsie was becalmed throughout the day, leaving the mid-cap FTSE 250 to claim the limelight
GlaxoSmithkline - Broker downgrade wipes £1.4bn from the value of Europe's largest drug maker
Citi has gone to ‘neutral’ from ‘buy’ on GSK shares, which it reckons are worth £17 each
GlaxoSmithKline and AstraZeneca among drug stocks buoyed by Trump’s healthcare plans
The Republicans are looking to repeal Obamacare as well as trying to ease regulatory pressures in the industry
FTSE 100 ends lower as May makes offer for EU nationals
The UK blue chip index closed down around 15 points at 7,424
Clovis Oncology to raise US$250mln to build on ovarian cancer trial success
Rubraca is one of a new type of cancer treatment called PARP-inhibitors
Archive
The Rookie Investor: Learning not to get caught in the value trap
Sometimes a cheap stock is cheap for a reason, not just because it’s good value…
Liberum Capital downgrades European pharma sector to 'neutral', but remains positive on GlaxoSmithKline and AstraZeneca
The broker has been bullish on the sector since November’s US elections, in which time the sector has advanced 20%, or 12% in relative terms.
FTSE 100 closes lower as Britain heads to the polls
The blue chip FTSE 100 index closed 28 points down at 7,449
AstraZeneca raises initial US$200mln from sale of global rights to its Zomig treatment for migraines and cluster headaches
The Swiss firm will pay AstraZeneca US$200mln upon completion of the deal, and AstraZeneca will also receive up to an additional $102mln in future milestone payments
Investments and investor services
FTSE 100 closes below 7,500 ahead of UK election
FTSE 100 closed below the 7,500 level as traders sit and wait it out..
ASCO 2017: AstraZeneca’s breast cancer treatment leads the way
There were also promising readouts from a prostate cancer trial and an early-stage ovarian cancer study
AstraZeneca’s Lynparza breast cancer drug impresses in phase III trial
The results bode well for Astra, which is looking to build a successful oncology franchise
Archive
It's all (about) the election stupid
Election to dominate as polls suggest a turbulent week ahead while cancer forum will put spotlight on pharma
AstraZeneca PLC 'one for the brave', but still a 'buy', according to leading City broker
“It would be easy to downgrade Astra here,” said analyst Roger Franklin.
Synairgen pleased with the progress made with the LOXL2 programme
The company is pleased with the progress made with the LOXL2 programme and clearly is not giving up on its IFN-beta candidate
Lung cancer success means AstraZeneca now has a “significant lead” over competitors
That’s according to Deutsche Bank, but analysts at HSBC aren’t quite so sure
Nasdaq puts S&P 500 and Dow in the shade - again
It's a case of "in for a Penney, in for a pounding" today
AstraZeneca, Merck and Bristol-Myers vying for dominance in lung cancer market
Merck seems to be ahead in the race to develop the number one lung cancer treatment, but for how long?
AstraZeneca reports “highly encouraging” initial results from its PACIFIC lung cancer trial
It bodes well for the upcoming readout of the MYSTIC trial which is what investors and the markets are really waiting for
FTSE 100 closes at record high after third-straight week of gains
At the close, the UK blue chip index was up 0.7%, or 48.8 points at 7,435.4, not far below its all-time record of 7,447.0
Investments and investor services
FTSE 100 finishes little changed after "Super Thursday" underwhelms
The Footsie was back in black - but only just - thanks to precious metals miners
US Food & Drug administration gives accelerated approval to drug that uses body’s immune system to fight cancer
The company estimates Imfinzi could eventually become a blockbuster product with peak sales of US$6.5bn.
AstraZeneca’s new drugs can’t come quick enough
Copycat competition for big sellers such as cholesterol-buster Crestor ate into first quarter revenues, which fell by 12% to US$5.54bn in the first-quarter.
Herencia Resources and Afarak gain, shares in Turbo Power Systems head south
Herencia Resources is a high riser among London's small caps today as it prepares a drill plan to enhance its copper projects
Synairgen believes interferon beta candidate has potential
The company, which developed and out-licensed AZD9412, believes the interferon beta candidate has potential.
Circassia Pharmaceuticals posts big 2016 loss after allergy disappointments
Circassia booked restructuring costs and impairments of £80.0mln in 2016 leading it to report a pretax loss of £144.9mln, up from a £62.8mln loss in 2015
Archive
BHP Billiton and banks dominate big week for blue chips
Week ahead: Huge for blue chip announcements with four high street banks, the UK’s two pharma giants, mining titans Anglo and BHP and restaurant to coffee chain Whitbread just a few of those updating.
Archive
Back to the dog pound: Dogs of the Footsie outperform in 2017
At the end of January, John Harrington tweaked the famous investment strategy known as the Dogs of the Dow, and applied it to UK stocks. How are the investments doing?
Drugs giant AstraZeneca's recommendation cut by Jefferies
“We and consensus have been guilty of failing to reflect the impact of future revenue externalisation and asset disposals on revenue and earnings per share growth,” said analyst Jeffrey Holford.
Merck receives diabetes drug labelling setback
Merck received a Complete Response Letter from the US Food and Drug Administration on the use of Sitagliptin
Archive
Rookie Investor: Finding out the easy way the importance of a stop-loss
The Rookie Investors has still got the Fever(tree), but would he have done had he set a stop-loss?
AstraZeneca’s diabetes drug data shows significant cut in death rates
A study of more than 300,000 people spanning six countries showed Farxiga significantly cut the risk of death or heart failure in diabetes sufferers
Investments and investor services
FTSE 100 ends little changed as UK lines up on Brexit grid
The druggies and miners were on offer early on – although the movements were barely perceptible on a lacklustre Monday morning.
Astra collaboration breathes new life into Circassia
The transaction provides an opportunity to transform Circassia's product portfolio and commercial presence.
Metal Tiger buoyed by strong response to partner's fund raise
Main share price risers and fallers in London at 4pm: Metal Tiger, Ilika
FDA deals another blow to AstraZeneca’s ZS-9 blood drug
ZS-9 is a treatment for hyperkalaemia – a condition where potassium levels in the blood are too high
Archive
Rookie Investor: The story so far
As I venture into the world of equity trading, here’s the background to my story and where I’m at now
FTSE shares end lower as sterling marks 8-week low vs dollar on Brexit jitters
FTSE 100 shares closed lower on Tuesday after investors turned edgy over Brexit plans which hit banking and retail shares as well as took sterling to an 8-week low against the US dollar
Hutchison China MediaTech reports record 2016 revenue as commercial sales rise
The biopharma company said it has made progress on the development of several cancer treatments
Barclays Capital analysts "resoundingly positive" on pharma stocks; AstraZeneca top pick
“Our clear preference is for specialty-focus and growth in the context of a strong-catalyst driven thematic or deep value,” Barclays said in a brief note to clients.
US FDA approves AstraZeneca combination drug for treatment of type-2 diabetes
The new once-daily medicine is to improve blood sugar level control in adults where single treatments of the drugs have proved inadequate.
AstraZeneca sells commercial rights to Zoladex cancer treatment
Astrazeneca has offloaded the US and Canada commercial rights of Zoladex to focus on new oncology medicines.
Drugs-crazed shoot-out: which investment is best out of Astra, Glaxo and Shire?
We’ve had the final results from Holy Trinity of the UK pharma industry ... which is the one to back?
AstraZeneca reveals positive breast cancer treatment trial results; Woodford adds to holding
AstraZeneca said patients treated with Lynparza showed a statistically-significant and clinically-meaningful improvement in progression-free survival.
Investments and investor services
FTSE 100 ends higher as food groups power gains on takeover battle
Around 3.15pm, the UK blue chip index was up over 21 points at 7,299, not far from the day’s peak of 7,307, and well above the day’s low of 7,253.
Metal Tiger strongly extends yesterday's leap; Laura Ashley drops
The main risers and fallers around 2.45pm included Metal Tiger, CloudTag, Laura Ashley ...
Investments and investor services
FTSE shares ease with lower Wall St and ex-dividend stocks
FTSE 100 shares closed lower, dragged down by weaker US stocks and a flurry of ex-dividend stocks in London
Investments and investor services
Day Ahead: Shire the big draw with sales of new drug closely monitored
Shire’s results Thursday will update on how 2016 ended as it provides commentary and numbers on the fourth quarter, which will be consolidated to provide full-year numbers too.
Archive
Week ahead: Shire continues pharma newsflow; Rolls-Royce results also key
Shire will complete the fourth-quarter results announcements from the FTSE 100-listed pharma giants following numbers from Astra and Glaxo
Archive
Week ahead: BP and Glaxo to continue trading trends for oil and drug giants
BP could please on Thursday as its recent quarterly updates have proved a little disappointing. GlaxoSmithKline will unveil its numbers Wednesday.
AstraZeneca: Never mind the sales, look at the dividend yield
The important number for the mainly income-hunting investor base was the dividend, which was bumped up to US$2.80 a share – providing a chunky yield in excess of 5%.
Investments and investor services
FTSE shares rise after sterling hit by dovish Bank of England report
The BoE said the UK economy will grow substantially faster than its downgraded forecasts made in the wake of last June's shock Brexit vote.
Archive
Will Vodafone’s third quarter disappoint?
Vodafone, Astrazeneca and Vedanta are among the blue-chips due to report on Thursday.
Selectively breeding the Dogs of the Footsie
The normally reliable investment strategy based on the "Dogs of the Dow" system has had a bad couple of years; what if we tweaked it?
Archive
Selectively breeding the Dogs of the Footsie
The normally reliable investment strategy based on the "Dogs of the Dow" system has had a bad couple of years; what if we tweaked it?
Archive
Week Ahead: Shell expected to announce unchanged dividend for 2017
Big names reporting this week: SSE, TalkTalk, AstraZeneca, Compass, Vedanta
FTSE 100 shares sink as pound ascends on Trump disquiet
FTSE 100 stocks fell further below 7200 on Monday after sterling gained strength against the US dollar in the aftermath of President Donald Trump's inauguration speech
Bristol-Myers shares hit by new lung cancer disappointment
It made the decision about the Opdivo and Yervoy combination after assessing the data available
FTSE 100 shares swing but close below 7200
FTSE 100 shares swung on Friday but ended down 10 points and below 7200 as the 45th President of the United States was being sworn in
AstraZeneca rejigs MYSTIC lung cancer study
The ‘pivotal’ study will now look at overall survival rather than just progression-free survival
FTSE 100 shares hit 11th successive record high as sterling dips
FTSE 100 shares did it again on Thursday – the 11th successive record high close – as turbulence in sterling finally gave in to a further steady decline and helped push stocks higher. All except retailers, that is
Archive
Sirius Minerals named among the ‘top tips’ for 2017
Here we take a look at the medium and small cap companies included among Fleet Street's top stock market tips for 2017.
Brexit and Trump key to how 2017 unfolds
Richard Hunter is keeping tabs on AstraZeneca, GSK and ITV as we head into 2017
Investments and investor services
FTSE 100 ends above 7,000 for first time since late October
FTSE 100 shares closed back above 7,000 on Friday for the first time since late October
AstraZeneca cancer drug application accepted by FDA
AstraZeneca’s application to use its closely-watched new drug durvalumab to treat bladder cancer has been accepted by US regulator, the Food and Drug Administration
AstraZeneca top pick under UBS's new valuation method
The conventional forecasting tool-box is broken says the Swiss broker
FTSE 100 stocks march higher, miners lead
FTSE 100 stocks marched higher on Wednesday with miners the top gainers
Five reasons to buy AstraZeneca
The general consensus is that the decline in AstraZeneca’s share price now represents a good buying opportunity
AstraZeneca's MYSTIC trial has little appeal for JP Morgan
The broker’s target price drops to £46 from £49 and the rating remains hold.
AztraZeneca a bargain, says this stock picker
The unwinding of bid speculation has meant AZ has lost around 15% of its value in the last six months.
FTSE 100 closed firm but volumes thin
FTSE 100 shares managed to recover enough to close Friday firmer but volumes were held back by the half-day trading in New York following Thanksgiving holiday on Thursday
AstraZeneca restarts cancer drug trials after US all clear
The two trials, KESTREL and EAGLE, are for head and neck cancer sufferers
Is too great a risk of MYSTIC failure factored into AstraZeneca's price?
Berenberg ascribes a 75% chance of success for the MYSTIC first-line lung cancer study, whereas the market seems more sceptical
It's all about the pipelines for drugs giants Astra and Shire
Exane has a target price of 5,100p for Astra, versus a current price of 4,406p. DB’s valuation of 6,200p per share for Shire is more than a tenner above the current price of around 5,020p.
AstraZeneca trial shows benefit of child asthma treatment
The improvement demonstrated the drug's appropriateness as a step-up therapy in young children
Immuno-therapy trials key for AstraZeneca says broker
Astra’s revenues fell 4% in the three months to September to US$5.7bn
AstraZeneca a highlight for a busy City schedule for Thursday
AstraZeneca, Vedanta, Halfords, and SuperGroup were among those in Thursday's diary.
Risers and fallers: Fresnillo glistens, while Tate's in a state
Some of the main news-driven share price changes at 3.30pm.
Drugs stocks boosted by Clinton defeat
Markets have reacted badly to Trump's electoral victory, but some sectors have benefited
Archive
Brokers: UK pharma giants in good shape if Clinton wins says Citigroup
“From a legislative angle, we continue to prefer names with either limited part D exposure [US Medicare] or heavier contribution of non-pharma assets."
Week Ahead: US election takes centre stage
Aside from the election, several UK retailers have results due next week
Investments and investor services
FTSE 100 drops on miners and drugs
FTSE 100 shares fell on Monday led by pharma Hikma
Proactive news summary – Mirada, Tissue Regenix, Synairgen and Vast Resources
A selection of the day's significant news stories from the junior AIM market
Archive
Salesforce.com gets battered but it has a fan in Exane
Exane is less concerned about any potential bid by Salesforce.com for Twitter than it is about the exciting deal it has just done